// App-Quantinova.ai

3915 : The Number Of Peg-Asparaginase Doses Administered Is a Determinant Of Relapse Risk In Adult ALL Treated With a Pediatric-Like Regimen

Researchers

Presenter

  • Ibrahim Aldoss

Principal Investigators

  • Vinod Pullarkat

  • Daniel Martinez

  • Lingyun Ji

  • Dan Douer

Medical Centers

  • hematology/Transplant, University of Southern California, Los Angeles, CA

  • University of Southern California, Los Angeles, CA

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Department of Pathology, University of Southern California, Los Angeles, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Acute lymphoblastic leukemia

  • Hyperbilirubinemia

  • Pancreatitis

  • Anaphylaxis

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

  • Venous thrombosis

Biomarkers

  • Breakpoint Cluster Region

  • White Blood Cell

Drug/Treatment

  • PEG-asparaginase

  • Pegaspargase

  • Oncaspar

  • Asparaginase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved